AcquisitionSep 14, 2026Pending
🇨🇭 Switzerland
SASantersus AGXBXenetic Biosciences, Inc.
Healthcare › Biotechnology
Deal valueUndisclosed
AnnouncedSep 14, 2026
ConsiderationStock
StructureNot stated
RegionEurope
Cross-borderYes
Contingent paymentNo
Overview
Xenetic Biosciences, Inc. agreed to acquire Santersus AG from the sellers in exchange for shares of Xenetic common stock, with Santersus becoming a wholly-owned subsidiary of Xenetic.
Deal rationale
Santersus's board determined the transaction is in the best interests of Santersus, and Xenetic's special committee determined the acquisition consideration is fair to and in the best interests of Xenetic and its stockholders.
AI-generated from the SEC filingPendingHealthcare › BiotechnologySwitzerlandEurope
Timeline
Valuation and terms
| Equity value | Undisclosed | |
|---|---|---|
| Enterprise value | Undisclosed | |
| Consideration | Stock |
Advisors
Buy-side
CGCanaccord Genuity
Sell-side
None listed
Parties
Target
SASantersus AG
- Headquarters
- Switzerland
- Ticker
- —
Acquirer
XBXenetic Biosciences, Inc.
- Headquarters
- United States
- Ticker
- —
Seller
SLSellers listed on Schedule I hereto
- Headquarters
- —
- Ticker
- —